Latest Exclusive Distribution Agreements News

Thrive Tribe Technologies has repositioned WooBoard and REFFIND towards defence and workforce software, but its FY26 annual report flags a material uncertainty over the company’s ability to continue as a going concern. The pivot follows a $3.66 million loss, $2.57 million operating cash outflow and another $1 million placement after year-end.

Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.

Thrive Tribe Technologies (ASX:1TT) has landed a three-year exclusive distribution agreement with Canadian NATO-registered defence contractor Effective Acceleration Ventures (EAV) to roll out its WooBoard and REFFIND platforms across NATO military forces.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.

Mastermyne Group Limited (ASX:MYE) delivered a robust FY26 with revenue up 13% to $237.7 million and underlying profit before tax surging 148% to $15.7 million, supported by contract wins and a record order book.

Stealth Group Holdings has posted record FY26 results with an 86% jump in net profit, driven by the transformative acquisition of Hardware & Building Traders. The company upgrades its FY28 sales target to $500 million, underpinned by expanded scale and integration synergies.

Skin Elements has secured an exclusive New Zealand distribution agreement for its ECO-Nurture bio-stimulant, raised $1.47 million through options and placement, and refreshed its board after shareholder votes.

Sprintex boosted its commercial footprint in the June quarter with a 65% order book increase from Mest Water, a paid trial at Taiwan's TSMC, and Dutch regulatory clearance lifting key uncertainties.

Lumos Diagnostics is accelerating the rollout of its rapid FebriDx test in the US, with a top 100 urgent care group deploying across 30+ sites and three tier 1 groups validating the test across 230+ locations.

Memphasys delivered a record $150,000 quarterly revenue, secured its largest Felix™ supply contract with Monash IVF, and expanded into UK and Southeast Asian IVF markets, positioning for accelerated growth in FY27.

Memphasys has locked in a three-year exclusive distribution agreement for its Felix™ sperm separation system in Thailand, targeting a key IVF market with 110 clinics and 20,000–30,000 cycles annually. The deal adds approximately A$430,500 in contracted revenue, lifting South-East Asian minimum contracts to about A$1 million and contributing to FY2026 Felix™ sales now exceeding A$3 million.